119 related articles for article (PubMed ID: 9420063)
1. Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment.
Schaad HJ; Petty BG; Grasela DM; Christofalo B; Raymond R; Stewart M
Antimicrob Agents Chemother; 1997 Dec; 41(12):2793-6. PubMed ID: 9420063
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis.
Grasela DM; Stoltz RR; Barry M; Bone M; Mangold B; O'Grady P; Raymond R; Haworth SJ
Antimicrob Agents Chemother; 2000 Aug; 44(8):2149-53. PubMed ID: 10898689
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.
Wade NA; Unadkat JD; Huang S; Shapiro DE; Mathias A; Yasin S; Ciupak G; Watts DH; Delke I; Rathore M; Hitti J; Frenkel L; Samelson R; Smith ME; Mofenson L; Burchett SK
J Infect Dis; 2004 Dec; 190(12):2167-74. PubMed ID: 15551216
[TBL] [Abstract][Full Text] [Related]
4. Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing.
Innes S; van der Laan L; Anderson PL; Cotton M; Denti P
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104267
[TBL] [Abstract][Full Text] [Related]
5. Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.
Kaul S; Christofalo B; Raymond RH; Stewart MB; Macleod CM
Antimicrob Agents Chemother; 1998 Sep; 42(9):2295-8. PubMed ID: 9736552
[TBL] [Abstract][Full Text] [Related]
6. Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.
Sy SK; Malmberg R; Matsushima A; Asin-Prieto E; Rosenkranz B; Cotton MF; Derendorf H; Innes S
Int J Antimicrob Agents; 2015 Apr; 45(4):413-9. PubMed ID: 25697412
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
Kline MW; Fletcher CV; Harris AT; Evans KD; Brundage RC; Remmel RP; Calles NR; Kirkpatrick SB; Simon C
J Pediatr; 1998 Mar; 132(3 Pt 1):543-6. PubMed ID: 9544920
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
[TBL] [Abstract][Full Text] [Related]
9. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
[TBL] [Abstract][Full Text] [Related]
10. Modified Release Biodegradable Polymeric Microspheres of Stavudine: Cell Viability, Cellular Uptake, Hemolysis Studies and In Vivo Pharmacokinetics.
Srivastava S; Kumar R; Arora SK; Sinha VR
Curr HIV Res; 2015; 13(6):503-16. PubMed ID: 26103967
[TBL] [Abstract][Full Text] [Related]
11. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
12. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
Monif T; Reyar S; Tiwari HK; Tippabhotla SK; Khuroo A; Thudi NR; Ahmed S; Raghuvanshi R
Arzneimittelforschung; 2009; 59(2):104-8. PubMed ID: 19338141
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.
Kline MW; Dunkle LM; Church JA; Goldsmith JC; Harris AT; Federici ME; Schultze ME; Woods L; Loewen DF; Kaul S
Pediatrics; 1995 Aug; 96(2 Pt 1):247-52. PubMed ID: 7630678
[TBL] [Abstract][Full Text] [Related]
14. dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
Skowron G
Antivir Ther; 1998; 3 Suppl 4():61-2. PubMed ID: 10723513
[TBL] [Abstract][Full Text] [Related]
15. A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients.
Piscitelli SC; Kelly G; Walker RE; Kovacs J; Falloon J; Davey RT; Raje S; Masur H; Polis MA
Antimicrob Agents Chemother; 1999 Mar; 43(3):647-50. PubMed ID: 10049281
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; Diaz C; Yogev R; McKinney RE; Abrams EJ; Mofenson LM
Pediatrics; 1999 May; 103(5):e62. PubMed ID: 10224206
[TBL] [Abstract][Full Text] [Related]
17. Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.
Sy SK; Innes S; Derendorf H; Cotton MF; Rosenkranz B
Antimicrob Agents Chemother; 2014; 58(2):1084-91. PubMed ID: 24295968
[TBL] [Abstract][Full Text] [Related]
18. Chronic stavudine exposure induces hepatic mitochondrial toxicity in adult Erythrocebus patas monkeys.
Gerschenson M; Nguyen VT; St Claire MC; Harbaugh SW; Harbaugh JW; Proia LA; Poirier MC
J Hum Virol; 2001; 4(6):335-42. PubMed ID: 12082400
[TBL] [Abstract][Full Text] [Related]
19. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
[TBL] [Abstract][Full Text] [Related]
20. Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment.
Cornejo-Juárez P; Sierra-Madero J; Volkow-Fernández P
Arch Med Res; 2003; 34(1):64-9. PubMed ID: 12604378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
